RedHill Biopharma is a small Israeli specialty biopharmaceutical company focused on GI diseases, infectious diseases, and oncology, primarily targeting the U.S. market. RedHill's only commercial product is Talicia, an FDA-approved all-in-one oral capsule combining omeprazole, amoxicillin, and rifabutin for treating H. pylori infection in adults. Talicia has FDA market exclusivity until 2027 and patent protection through 2042. RedHill commercializes Talicia in the U.S. through Talicia Holdings, a joint venture in which RedHill holds a 70% stake and partner Cumberland Pharmaceuticals contributes its national sales force. Net U.S. revenues are split equally between RedHill and Cumberland. Talicia has also been launched in the UAE and Gulf Cooperation Council countries through a license agreement with Gaelan Medical. Beyond Talicia, RedHill has five clinical-stage pipeline candidates. The most advanced is opaganib, an oral SK2 inhibitor being studied across prostate cancer, cholangiocarcinoma, CLL, and COVID-19-related ARDS. RHB-102 (Bekinda), an extended-release formulation of ondansetron, is being developed for acute gastroenteritis, IBS, and GLP-1-associated GI side effects. RHB-204, a fixed-dose antibiotic combination, is being repositioned toward MAP-positive Crohn's disease following positive Phase 3 results from its predecessor, RHB-104. None of the pipeline candidates generate revenue. RedHill funds pipeline development primarily through government grants, investigator-sponsored trials, and licensing partnerships, reflecting significant capital constraints as a pre-profitability company.